UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 11-K
(Mark One)
x ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2024
OR
o TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______to _______
Commission file number: 001-12215
A. Full title of the plan and the address of the plan, if different from that of the issuer named below:
THE QUEST DIAGNOSTICS PROFIT SHARING PLAN
B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
QUEST DIAGNOSTICS INCORPORATED
500 PLAZA DRIVE
SECAUCUS, NJ 07094
The Quest Diagnostics Profit Sharing Plan
Index to Financial Statements and Supplemental Schedule
| Page | |||||
| Financial Statements | |||||
| Supplemental Schedule* | |||||
| * Other schedules required by Section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable. | |||||
| Exhibit | |||||
Report of Independent Registered Public Accounting Firm
Plan Administrator and Plan Participants
The Quest Diagnostics Profit Sharing Plan
Opinion on the financial statements
We have audited the accompanying statements of net assets available for benefits of The Quest Diagnostics Profit Sharing Plan (the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.
Basis for opinion
These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Supplemental information
The schedule of assets (held at end of year) as of December 31, 2024 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.
/s/ GRANT THORNTON LLP
We have served as the Plan's auditor since 2008.
Melville, New York
June 20, 2025
1
The Quest Diagnostics Profit Sharing Plan
Statements of Net Assets Available for Benefits
December 31, 2024 and 2023
(in thousands)
| 2024 | 2023 | ||||||||||
| Assets | |||||||||||
Investments, at fair value | $ | 5,483,306 | $ | 5,050,535 | |||||||
Receivables | |||||||||||
| Employer contributions receivable | — | 31 | |||||||||
| Notes receivable from participants | 70,809 | 75,659 | |||||||||
| Investment related receivables | 1,031 | 770 | |||||||||
| Total receivables | 71,840 | 76,460 | |||||||||
| Total assets | 5,555,146 | 5,126,995 | |||||||||
| Liabilities | |||||||||||
| Investment related payables | 1,376 | 850 | |||||||||
Net assets available for benefits | $ | 5,553,770 | $ | 5,126,145 | |||||||
The accompanying notes are an integral part of these financial statements.
2
The Quest Diagnostics Profit Sharing Plan
Statement of Changes in Net Assets Available for Benefits
For the Year Ended December 31, 2024
(in thousands)
| Additions: | |||||
| Investment income | |||||
| Net appreciation in fair value of investments | $ | 734,863 | |||
| Dividends and interest | 20,076 | ||||
| Total investment income | 754,939 | ||||
| Interest income on notes receivable from participants | 5,420 | ||||
| Contributions | |||||
| Employer | 100,667 | ||||
| Participants | 191,222 | ||||
| Rollovers | 42,978 | ||||
| Total contributions | 334,867 | ||||
| Total additions | 1,095,226 | ||||
| Deductions: | |||||
| Benefits paid to participants | 665,328 | ||||
| Administrative expenses | 2,273 | ||||
| Total deductions | 667,601 | ||||
| Net increase | 427,625 | ||||
| Net assets available for benefits: | |||||
| Beginning of year | 5,126,145 | ||||
| End of year | $ | 5,553,770 | |||
The accompanying notes are an integral part of these financial statements.
3
The Quest Diagnostics Profit Sharing Plan
December 31, 2024 and 2023
Notes to Financial Statements (dollars in thousands)
1. Description of the Plan
Background - The Quest Diagnostics Profit Sharing Plan (the “Plan”) is a defined contribution plan. The Plan was established by Quest Diagnostics Incorporated ("Quest Diagnostics" or the "Company"), which is the parent entity of a controlled group of corporations and other entities (the "Quest Control Group"). Effective August 15, 2021, sponsorship of the Plan was transferred from the Company to Quest Diagnostics Clinical Laboratories, Inc. (the "Plan Sponsor"), a wholly owned subsidiary of the Company. The Plan provides retirement benefits to eligible employees of the Quest Control Group. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The following description of the Plan provides only general information. Participants should refer to the plan document for a more complete description of the Plan's provisions.
Eligibility and Participant Contributions - The Plan provides for participant-directed investment of their voluntary contributions and employer matching contributions in a number of investment funds. Eligible employees can participate in the Plan as soon as administratively feasible upon becoming an employee of a member of the Quest Control Group. Participants may contribute an amount between 1% and 35% of their eligible compensation, as defined, for the contribution period. Catch-up contributions, as defined in the Internal Revenue Code (the "Code"), are permissible for eligible participants. Participants may modify their contribution percentage at any time. Participants may also choose to make rollover contributions to the Plan of amounts received from an eligible defined benefit or defined contribution plan maintained by another company. Contributions are subject to Code limitations.
Employer Matching Contributions - Members of the Quest Control Group match 100% of a participant's contribution, up to 5% of eligible compensation, in cash after the participant completes 12 months of service, as defined, with the Quest Control Group. Employer matching contributions are remitted to the Plan at the same time that the corresponding participants' contributions are remitted.
Participant Accounts - A separate individual account is established for each Plan participant. Each participant's account is credited with the participant's contributions and the employer matching contributions, plus the allocation of investment earnings, gains and losses and expenses, based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.
Revenue sharing credits, which are considered parties-in-interest transactions, are allocated back to participants investing in respective investment funds which generate such credits.
Vesting - Participants immediately vest in their voluntary contributions and employer matching contributions plus actual earnings thereon. Certain participants who were active in plans sponsored by previous employers have vesting requirements applied to their previous employer contribution accounts consistent with the vesting requirements in effect before the assets were merged into the Plan.
Investment Options - Participants may elect to have their voluntary contributions and employer matching contributions invested in any or all of the available investment options, most of which are managed by Fidelity Management & Research Company (“FMRC”) and its affiliates. Participants may also elect to have their voluntary contributions and employer matching contributions invested in shares of the Company's common stock through the Quest Diagnostics stock fund. Participants have the ability to modify their investment elections daily, subject to certain short-term trading restrictions imposed by FMRC and its affiliates and the Company's securities trading policy, which prohibits trading in the Company's common stock on a short-term basis and while in possession of material non-public information about the Company.
Participants cannot contribute greater than 25% per pay period of pre-tax contributions into the Quest Diagnostics stock fund. In addition, participants can transfer monies into the Quest Diagnostics stock fund only to the extent the percentage of holdings in the Quest Diagnostics stock fund after the transfer remains below 25% of the participant's entire account balance.
Participants may elect to receive their dividends on investments in the Quest Diagnostics stock fund as a taxable cash payment or to have those dividends automatically reinvested.
4
The Quest Diagnostics Profit Sharing Plan
December 31, 2024 and 2023
Notes to Financial Statements (dollars in thousands) - continued
Distribution Options - Participants can elect to have their benefit distributions, equal to the value of the vested portion of their account balance, paid in the form of a partial or lump sum distribution, a direct rollover into another eligible retirement plan or traditional individual retirement account, installment payments, or for certain assets, an annuity.
Withdrawals - Withdrawals may be made for qualified emergencies, as defined in the Code. Depending upon the type of withdrawal and the status of the contribution, penalties upon withdrawal may apply. Participants may also begin to make withdrawals without penalty at age 59 ½, subject to certain limitations as defined by the Plan.
Forfeitures - Employer contributions in forfeited nonvested accounts may be used to reduce future employer contributions or pay the Plan's expenses. The forfeiture activity and account balance was not material as of and for the years ended December 31, 2024 and 2023.
Parties-in-Interest - Certain investments of the Plan, as of December 31, 2024 and 2023, are shares of mutual funds and collective funds managed by FMRC and its affiliates. These transactions qualify as party-in-interest transactions.
The Company also is a party-in-interest to the Plan under the definition provided in Section 3(14) of ERISA. Therefore, Quest Diagnostics stock transactions qualify as party-in-interest transactions. As of December 31, 2024 and 2023, the total fair value of the Plan's investment in Quest Diagnostics stock was $295,103 and $295,841, respectively. During 2024, there were no purchases of Quest Diagnostics stock by the Plan and sales of Quest Diagnostics stock by the Plan were $26,895.
Notes Receivable from Participants - Participants are permitted to obtain loans in amounts not less than one thousand dollars and up to the lesser of (1) fifty thousand dollars, subject to certain limitations as defined by the Plan, or (2) 50% of the participant's vested portion of their account value. Except with respect to pre-existing loans transferred or merged into the Plan and as set forth below, a participant may have only one outstanding loan at a time and loans are repayable over a period of up to five years, unless the proceeds are used to purchase a primary residence, in which case a period of up to ten years (effective January 2025, thirty years) is permitted. Loans are secured by one-half of a participant's vested account balance and bear interest at prime plus 1%. Rates range from 3.25% to 9.50%; maturities vary by participant. Principal and interest are repaid to the Plan through payroll deductions for active employees. Participants can elect to pay the entire outstanding balance of a loan directly to Fidelity Management Trust Company ("FMTC"). Actively employed participants can also submit a partial loan repayment directly to FMTC outside the normal payroll deductions, accelerating the payoff date. Participants who are no longer active employees may continue to repay outstanding loan balances directly to FMTC.
In addition, notes receivable from participants qualify as party-in-interest transactions. As of December 31, 2024 and 2023, the carrying value of the Plan's notes receivable from participants was $70,809 and $75,659, respectively.
Plan Administration - The plan administrator is the Benefits Administration Committee (the "Plan Administrator"), which is appointed by the Plan Sponsor's Board of Directors. The Plan's trustee and recordkeeper for the Plan investments are FMTC and Fidelity Investments Institutional Operations Company LLC, respectively.
Tax Status - The Internal Revenue Service (“IRS”) has determined and informed the Company by letter dated September 22, 2014, that the Plan and related trust are designed in accordance with applicable sections of the Code. The Plan Sponsor believes that the Plan, which has been amended since the IRS determination, continues to be designed and operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan is qualified and related trust is tax-exempt.
Accounting principles generally accepted in the United States (“US GAAP”) requires the Plan Administrator to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024 and 2023 there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing authorities; however, there are currently no audits for any tax periods in progress.
Administrative Expenses - Plan administrative expenses are paid by the Company to the extent not paid or offset by the Plan or the Quest Control Group. Fees associated with the administration of notes receivable from participants are charged
5
The Quest Diagnostics Profit Sharing Plan
December 31, 2024 and 2023
Notes to Financial Statements (dollars in thousands) - continued
directly against participant accounts. These fees are included in administrative expenses and are expensed when incurred. Investment related expenses are included in net appreciation of fair value of investments.
Investment Management Fees - Investment management fees and operating expenses charged to the Plan for investments in the Plan are deducted from income earned on a daily basis and are not separately reflected. Consequently, investment management fees and operating expenses are reflected as a reduction of investment return for such investments.
Plan Termination - The Plan Sponsor intends to continue the Plan indefinitely, but reserves the right to change or discontinue the Plan at its discretion. Participants will become fully vested in their rights under the Plan if it is terminated or if employer matching contributions are completely discontinued.
2. Summary of Significant Accounting Policies
Basis of Presentation - The Plan maintains its financial records on the accrual basis of accounting.
Use of Estimates - The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, if any, at the date of the financial statements and the reported amounts of additions to and deductions from net assets during the reporting period. Actual results could differ from those estimates.
Risks and Uncertainties - Certain underlying investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, changes in these risks could materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.
Benefits paid to participants - Benefits payments to participants are recorded when paid.
Valuation of Investments - Investments are stated at fair value at year end. Refer to Note 3 for additional information related to the valuation of Plan investments.
Security Transactions and Income - Purchases and sales of securities are recorded on a trade-date basis. Dividend income is recorded on the ex-dividend date. Interest income from investments is recorded as earned on an accrual basis.
Net appreciation in fair value of investments represents the Plan's net realized and unrealized gains (losses) on investments held by the Plan.
Notes Receivable from Participants - Notes receivable from participants are valued at their unpaid principal balance, plus any accrued but unpaid interest. Interest income from notes receivable from participants is recorded on an accrual basis.
3. Fair Value Measurements
Fair value measurements are based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, and are determined by either the principal market or the most advantageous market.
Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.
6
The Quest Diagnostics Profit Sharing Plan
December 31, 2024 and 2023
Notes to Financial Statements (dollars in thousands) - continued
| Level 1: | Quoted prices in active markets for identical assets or liabilities. | ||||
Level 2: | Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. | ||||
| Level 3: | Valuations derived from valuation techniques in which one or more significant inputs are unobservable. | ||||
During the year ended December 31, 2024, there were no transfers between levels. During 2024, the Plan replaced the majority of its mutual fund investment options with collective funds.
The following table provides a summary of the assets in the Plan that are measured at fair value on a recurring basis:
| Basis of Fair Value Measurements | ||||||||||||||||||||||||||
| December 31, 2024 | Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||||
| Mutual funds | $ | 204,410 | $ | 204,410 | $ | — | $ | — | ||||||||||||||||||
| Quest Diagnostics common stock | 295,103 | 295,103 | — | — | ||||||||||||||||||||||
| Other common stock | 282,820 | 282,743 | — | 77 | ||||||||||||||||||||||
| Subtotal | $ | 782,333 | $ | 782,256 | $ | — | $ | 77 | ||||||||||||||||||
| Investments measured at NAV as a practical expedient: (A) | 4,700,973 | |||||||||||||||||||||||||
| Total investments, at fair value | $ | 5,483,306 | ||||||||||||||||||||||||
| Basis of Fair Value Measurements | ||||||||||||||||||||||||||
| December 31, 2023 | Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||||
| Mutual funds | $ | 2,897,613 | $ | 2,897,613 | $ | — | $ | — | ||||||||||||||||||
| Quest Diagnostics common stock | 295,841 | 295,841 | — | — | ||||||||||||||||||||||
| Other common stock | 246,567 | 246,498 | — | 69 | ||||||||||||||||||||||
| Subtotal | $ | 3,440,021 | $ | 3,439,952 | $ | — | $ | 69 | ||||||||||||||||||
| Investments measured at NAV as a practical expedient: (A) | 1,610,514 | |||||||||||||||||||||||||
| Total investments, at fair value | $ | 5,050,535 | ||||||||||||||||||||||||
(A) Certain investments, including the Collective Funds, that were measured at fair value using the net asset value ("NAV") per share (or its equivalent) practical expedient were not classified in the fair value hierarchy. There are no unfunded commitments or redemption restrictions related to these investments.
Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used as of December 31, 2024 and 2023.
Mutual Funds: Valued at the daily closing price reported by the fund. Mutual funds held by the Plan are open-ended mutual funds that are registered with the Security and Exchange Commission ("SEC") and are required to publish their NAV on a daily basis and to transact at that price. The mutual funds held by the Plan are classified as level 1.
7
The Quest Diagnostics Profit Sharing Plan
December 31, 2024 and 2023
Notes to Financial Statements (dollars in thousands) - continued
Quest Diagnostics Common Stock and Other Common Stock classified as level 1: Valued at the closing price reported on the active market on which the individual securities are traded.
Other Common Stock classified as level 3: Valued using a valuation technique based on available information, which may consider market-based valuation multiples; a discount or premium from market value of a similar, freely traded equity security of the same issuer; or some combination. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable.
Collective Funds: Valued at NAV per unit as determined by the trustee at year end. The NAV is used as a practical expedient to estimate fair value.
The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
4. Commitments and Contingencies
In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Plan. The complaint alleges, among other things, that the fiduciaries of the Plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. The Plan itself is not named as a defendant. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint. After discovery was completed, the Company filed a motion for summary judgment, which was granted. The matter is on appeal.
8
The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2024 (dollars in thousands)
| (a) | (b) Identity of Issue, Borrower, Lessor, or Similar Party | (c) Description | (d) Cost | (e) Current Value | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2010 T | Collective Fund | *** | $ | 18,786 | |||||||||||||||||||||
| * | Fidelity Freedom Blend 2015 T | Collective Fund | *** | 57,543 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2020 T | Collective Fund | *** | 164,860 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2025 T | Collective Fund | *** | 399,910 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2030 T | Collective Fund | *** | 580,480 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2035 T | Collective Fund | *** | 497,680 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2040 T | Collective Fund | *** | 380,813 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2045 T | Collective Fund | *** | 285,380 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2050 T | Collective Fund | *** | 186,708 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2055 T | Collective Fund | *** | 114,503 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2060 T | Collective Fund | *** | 60,792 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend 2065 T | Collective Fund | *** | 20,008 | ||||||||||||||||||||||
| * | Fidelity Freedom Blend Income T | Collective Fund | *** | 18,112 | ||||||||||||||||||||||
| * | Fidelity Managed Income Portfolio II - Class 3 | Collective Fund | *** | 164,273 | ||||||||||||||||||||||
| * | Fidelity Contrafund Comingled Pool | Collective Fund | *** | 420,121 | ||||||||||||||||||||||
| * | Fidelity OTC Comingled Pool | Collective Fund | *** | 344,261 | ||||||||||||||||||||||
| Spartan 500 Index Pool Class F | Collective Fund | *** | 659,448 | |||||||||||||||||||||||
| Spartan Extended Market Index Pool Class F | Collective Fund | *** | 50,659 | |||||||||||||||||||||||
| Spartan Total International Index Pool Class F | Collective Fund | *** | 35,486 | |||||||||||||||||||||||
| GW&K Small/Mid Cap Fund | Collective Fund | *** | 134,114 | |||||||||||||||||||||||
| Prudential Core Plus Bond Fund Class 15 | Collective Fund | *** | 22,333 | |||||||||||||||||||||||
| GQG Partners International Equity CIT Class D | Collective Fund | *** | 83,037 | |||||||||||||||||||||||
| State Street Short Term Investment Fund | Collective Fund | *** | 1,666 | |||||||||||||||||||||||
| Total Interest in Collective Funds | $ | 4,700,973 | ||||||||||||||||||||||||
| T Rowe Price Government Reserve Investment Fund | Mutual Fund | *** | $ | 804 | ||||||||||||||||||||||
| Vanguard Total Bond Market Index Fund - Institutional Plus Share Class | Mutual Fund | *** | 90,083 | |||||||||||||||||||||||
| * | Fidelity Investments Money Market Government Portfolio - Institutional Class | Mutual Fund | *** | 113,523 | ||||||||||||||||||||||
| Total Interest in Mutual Funds | $ | 204,410 | ||||||||||||||||||||||||
| * | Quest Diagnostics Incorporated | Common Stock | *** | $ | 295,103 | |||||||||||||||||||||
9
The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2024 (dollars in thousands)
| (a) | (b) Identity of Issue, Borrower, Lessor, or Similar Party | (c) Description | (d) Cost | (e) Current Value | ||||||||||||||||||||||
| Accenture Plc Cl A | Other Common Stock | *** | $ | 1,409 | ||||||||||||||||||||||
| Adobe Inc | Other Common Stock | *** | 1,611 | |||||||||||||||||||||||
| Advanced Micro Devices Inc | Other Common Stock | *** | 842 | |||||||||||||||||||||||
| Affirm Holdings Inc | Other Common Stock | *** | 227 | |||||||||||||||||||||||
| Agco Corp | Other Common Stock | *** | 998 | |||||||||||||||||||||||
| Alphabet Inc Cl A | Other Common Stock | *** | 13,286 | |||||||||||||||||||||||
| Amazon.Com Inc | Other Common Stock | *** | 15,375 | |||||||||||||||||||||||
| Ameren Corp | Other Common Stock | *** | 1,792 | |||||||||||||||||||||||
| American International Group | Other Common Stock | *** | 1,408 | |||||||||||||||||||||||
| Amphenol Corporation Cl A | Other Common Stock | *** | 3,075 | |||||||||||||||||||||||
| Apple Inc | Other Common Stock | *** | 17,566 | |||||||||||||||||||||||
| Argenx Se Sponsored Adr | Other Common Stock | *** | 1,300 | |||||||||||||||||||||||
| Asml Hldg Nv (Ny Reg Shs) New York Registered Shar | Other Common Stock | *** | 1,089 | |||||||||||||||||||||||
| Astrazeneca Plc Spons Adr | Other Common Stock | *** | 628 | |||||||||||||||||||||||
| Atlassian Corp Plc Cls A | Other Common Stock | *** | 1,427 | |||||||||||||||||||||||
| Aurora Innovation Inc | Other Common Stock | *** | 331 | |||||||||||||||||||||||
| Avalonbay Communities Inc Reit | Other Common Stock | *** | 1,887 | |||||||||||||||||||||||
| Bank of America Corporation | Other Common Stock | *** | 2,591 | |||||||||||||||||||||||
| Baxter Intl Inc | Other Common Stock | *** | 920 | |||||||||||||||||||||||
| Becton Dickinson & Co | Other Common Stock | *** | 3,182 | |||||||||||||||||||||||
| Biogen Inc | Other Common Stock | *** | 333 | |||||||||||||||||||||||
| Boeing Co | Other Common Stock | *** | 1,871 | |||||||||||||||||||||||
| Cf Industries Holdings Inc | Other Common Stock | *** | 936 | |||||||||||||||||||||||
| Chipotle Mexican Grill Inc | Other Common Stock | *** | 1,314 | |||||||||||||||||||||||
| Chubb Ltd | Other Common Stock | *** | 2,666 | |||||||||||||||||||||||
| Cigna Group (The) | Other Common Stock | *** | 2,859 | |||||||||||||||||||||||
| Citigroup Inc | Other Common Stock | *** | 1,633 | |||||||||||||||||||||||
| Coca Cola Co | Other Common Stock | *** | 721 | |||||||||||||||||||||||
| Colgate-Palmolive Co | Other Common Stock | *** | 1,036 | |||||||||||||||||||||||
| Comcast Corp Cl A | Other Common Stock | *** | 1,080 | |||||||||||||||||||||||
| Conagra Brands Inc | Other Common Stock | *** | 704 | |||||||||||||||||||||||
| Conocophillips | Other Common Stock | *** | 2,058 | |||||||||||||||||||||||
| Coupang Inc A | Other Common Stock | *** | 1,455 | |||||||||||||||||||||||
| Cummins Inc | Other Common Stock | *** | 1,708 | |||||||||||||||||||||||
| Cvs Health Corp | Other Common Stock | *** | 889 | |||||||||||||||||||||||
| Danaher Corp | Other Common Stock | *** | 1,217 | |||||||||||||||||||||||
| Disney (Walt) Co | Other Common Stock | *** | 1,301 | |||||||||||||||||||||||
| Dominion Energy Inc | Other Common Stock | *** | 509 | |||||||||||||||||||||||
10
The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2024 (dollars in thousands)
| (a) | (b) Identity of Issue, Borrower, Lessor, or Similar Party | (c) Description | (d) Cost | (e) Current Value | ||||||||||||||||||||||
| Dynatrace Inc | Other Common Stock | *** | $ | 832 | ||||||||||||||||||||||
| Elevance Health Inc | Other Common Stock | *** | 2,173 | |||||||||||||||||||||||
| Eli Lilly & Co | Other Common Stock | *** | 3,718 | |||||||||||||||||||||||
| Entegris Inc | Other Common Stock | *** | 1,149 | |||||||||||||||||||||||
| Eog Resources Inc | Other Common Stock | *** | 765 | |||||||||||||||||||||||
| Eqt Corporation | Other Common Stock | *** | 1,351 | |||||||||||||||||||||||
| Equifax Inc | Other Common Stock | *** | 1,495 | |||||||||||||||||||||||
| Equitable Holdings Inc | Other Common Stock | *** | 1,636 | |||||||||||||||||||||||
| Exxon Mobil Corp | Other Common Stock | *** | 2,103 | |||||||||||||||||||||||
| Fair Isaac Corp | Other Common Stock | *** | 1,258 | |||||||||||||||||||||||
| Fifth Third Bancorp | Other Common Stock | *** | 683 | |||||||||||||||||||||||
| Fiserv Inc | Other Common Stock | *** | 8,113 | |||||||||||||||||||||||
| Fortive Corp | Other Common Stock | *** | 787 | |||||||||||||||||||||||
| Ge Aerospace | Other Common Stock | *** | 1,512 | |||||||||||||||||||||||
| Ge Vernova Inc | Other Common Stock | *** | 522 | |||||||||||||||||||||||
| Hartford Insurance Group Inc/The | Other Common Stock | *** | 2,384 | |||||||||||||||||||||||
| Home Depot Inc | Other Common Stock | *** | 894 | |||||||||||||||||||||||
| Honeywell Intl Inc | Other Common Stock | *** | 1,062 | |||||||||||||||||||||||
| Howmet Aerospace Inc | Other Common Stock | *** | 1,472 | |||||||||||||||||||||||
| Hubspot Inc | Other Common Stock | *** | 1,539 | |||||||||||||||||||||||
| Huntington Bancshares Inc | Other Common Stock | *** | 1,175 | |||||||||||||||||||||||
| Ingersoll Rand Inc | Other Common Stock | *** | 1,428 | |||||||||||||||||||||||
| Intel Corp | Other Common Stock | *** | 396 | |||||||||||||||||||||||
| International Paper Co | Other Common Stock | *** | 1,383 | |||||||||||||||||||||||
| Intuit Inc | Other Common Stock | *** | 5,595 | |||||||||||||||||||||||
| Intuitive Surgical Inc | Other Common Stock | *** | 3,917 | |||||||||||||||||||||||
| Johnson & Johnson | Other Common Stock | *** | 1,765 | |||||||||||||||||||||||
| Kenvue Inc | Other Common Stock | *** | 2,727 | |||||||||||||||||||||||
| Kimberly Clark Corp | Other Common Stock | *** | 1,523 | |||||||||||||||||||||||
| L3Harris Technologies Inc | Other Common Stock | *** | 2,287 | |||||||||||||||||||||||
| Las Vegas Sands Corp | Other Common Stock | *** | 1,310 | |||||||||||||||||||||||
| Legend Biotech Corp Spon Adr | Other Common Stock | *** | 365 | |||||||||||||||||||||||
| Lululemon Athletica Inc | Other Common Stock | *** | 918 | |||||||||||||||||||||||
| Mastercard Inc Cl A | Other Common Stock | *** | 6,372 | |||||||||||||||||||||||
| Mercadolibre Inc | Other Common Stock | *** | 930 | |||||||||||||||||||||||
| Meta Platforms Inc Cl A | Other Common Stock | *** | 9,636 | |||||||||||||||||||||||
| Metlife Inc | Other Common Stock | *** | 1,457 | |||||||||||||||||||||||
| Microsoft Corp | Other Common Stock | *** | 22,278 | |||||||||||||||||||||||
11
The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2024 (dollars in thousands)
| (a) | (b) Identity of Issue, Borrower, Lessor, or Similar Party | (c) Description | (d) Cost | (e) Current Value | ||||||||||||||||||||||
| Natera Inc | Other Common Stock | *** | $ | 586 | ||||||||||||||||||||||
| Netflix Inc | Other Common Stock | *** | 3,107 | |||||||||||||||||||||||
| News Corp New Cl A | Other Common Stock | *** | 1,461 | |||||||||||||||||||||||
| Norfolk Southern Corp | Other Common Stock | *** | 1,767 | |||||||||||||||||||||||
| Nvidia Corp | Other Common Stock | *** | 17,267 | |||||||||||||||||||||||
| Philip Morris Intl Inc | Other Common Stock | *** | 1,678 | |||||||||||||||||||||||
| Qualcomm Inc | Other Common Stock | *** | 1,218 | |||||||||||||||||||||||
| Rexford Industrial Realty Inc | Other Common Stock | *** | 897 | |||||||||||||||||||||||
| Rockwell Automation Inc | Other Common Stock | *** | 1,258 | |||||||||||||||||||||||
| Ross Stores Inc | Other Common Stock | *** | 1,613 | |||||||||||||||||||||||
| Rpm International Inc | Other Common Stock | *** | 606 | |||||||||||||||||||||||
| Samsung Elec Vtg Gdr Regs | Other Common Stock | *** | 740 | |||||||||||||||||||||||
| Sanofi Spon Adr | Other Common Stock | *** | 749 | |||||||||||||||||||||||
| Schlumberger Ltd | Other Common Stock | *** | 1,661 | |||||||||||||||||||||||
| Schwab Charles Corp | Other Common Stock | *** | 3,418 | |||||||||||||||||||||||
| Sempra | Other Common Stock | *** | 1,224 | |||||||||||||||||||||||
| Servicenow Inc | Other Common Stock | *** | 3,379 | |||||||||||||||||||||||
| Shopify Inc Cl A | Other Common Stock | *** | 1,939 | |||||||||||||||||||||||
| Siemens Ag (Regd) | Other Common Stock | *** | 884 | |||||||||||||||||||||||
| Sonova Hldg Ag Unspon Adr | Other Common Stock | *** | 1,030 | |||||||||||||||||||||||
| Southern Co | Other Common Stock | *** | 1,512 | |||||||||||||||||||||||
| Southwest Airlines Co | Other Common Stock | *** | 722 | |||||||||||||||||||||||
| Stanley Black & Decker Inc | Other Common Stock | *** | 1,679 | |||||||||||||||||||||||
| Stripe Inc Class B Pp | Other Common Stock | *** | 77 | |||||||||||||||||||||||
| Stryker Corp | Other Common Stock | *** | 2,514 | |||||||||||||||||||||||
| Suncor Energy Inc | Other Common Stock | *** | 1,017 | |||||||||||||||||||||||
| Te Connectivity Plc | Other Common Stock | *** | 1,148 | |||||||||||||||||||||||
| Texas Instruments Inc | Other Common Stock | *** | 795 | |||||||||||||||||||||||
| The Booking Holdings Inc | Other Common Stock | *** | 2,911 | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc | Other Common Stock | *** | 1,625 | |||||||||||||||||||||||
| Totalenergies Se Adr | Other Common Stock | *** | 888 | |||||||||||||||||||||||
| Tradeweb Markets Inc A | Other Common Stock | *** | 785 | |||||||||||||||||||||||
| Union Pacific Corp | Other Common Stock | *** | 1,184 | |||||||||||||||||||||||
| United Parcel Service Inc Cl B | Other Common Stock | *** | 1,756 | |||||||||||||||||||||||
| Unitedhealth Group Inc | Other Common Stock | *** | 6,264 | |||||||||||||||||||||||
| Us Bancorp Del | Other Common Stock | *** | 1,126 | |||||||||||||||||||||||
| Viatris Inc | Other Common Stock | *** | 745 | |||||||||||||||||||||||
| Visa Inc Cl A | Other Common Stock | *** | 4,243 | |||||||||||||||||||||||
12
The Quest Diagnostics Profit Sharing Plan
EIN: #38-2084239 Plan: #333
Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)
December 31, 2024 (dollars in thousands)
| (a) | (b) Identity of Issue, Borrower, Lessor, or Similar Party | (c) Description | (d) Cost | (e) Current Value | ||||||||||||||||||||||
| Walmart Inc | Other Common Stock | *** | $ | 1,497 | ||||||||||||||||||||||
| Wells Fargo & Co | Other Common Stock | *** | 2,928 | |||||||||||||||||||||||
| Western Digital Corp | Other Common Stock | *** | 505 | |||||||||||||||||||||||
| Weyerhaeuser Co | Other Common Stock | *** | 1,737 | |||||||||||||||||||||||
| Williams Companies Inc | Other Common Stock | *** | 684 | |||||||||||||||||||||||
| Zimmer Biomet Hldgs Inc | Other Common Stock | *** | 1,852 | |||||||||||||||||||||||
| Total Interest in Other Common Stock | $ | 282,820 | ||||||||||||||||||||||||
| Investments at Fair Value | $ | 5,483,306 | ||||||||||||||||||||||||
| * | Notes Receivable from Participants** | Loans | $ | 70,809 | ||||||||||||||||||||||
| TOTAL | $ | 5,554,115 | ||||||||||||||||||||||||
| * | Party-in-interest to the Plan. | |||||||||||||||||||||||||
| ** | Rates range from 3.25% to 9.50%; maturities vary by participant. | |||||||||||||||||||||||||
| *** | The cost of participant-directed investments is not required to be disclosed. | |||||||||||||||||||||||||
13
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned, hereunto duly authorized.
June 20, 2025
The Quest Diagnostics Profit Sharing Plan
| By: | /s/ Cecilia K. McKenney | ||||
| Cecilia K. McKenney | |||||
| Senior Vice President, Chief Human Resources Officer and Member of the Benefits Administration Committee of Quest Diagnostics Clinical Laboratories, Inc. | |||||
14